Information Provided By:
Fly News Breaks for September 30, 2016
CVS
Sep 30, 2016 | 07:11 EDT
Leerink analyst David Larsen said that after speaking with a PBM and Managed Care specialist and performing an analysis of IMS data he now believes that drug pricing has slowed materially over the past 9 months. Given that conclusion, Larsen is lowering his revenue and EPS estimates for CVS Health for the second half of this year and for 2017 and lowered his price target on CVS shares to $105 from $110. However, he keeps an Outperform rating on the stock, since he is still positive on CVS for the long-term.
News For CVS From the Last 2 Days
There are no results for your query CVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.